Lp(a) is a macromolecular complex composed of one molecule of Low-Density Lipoprotein (LDL) containing apolipoprotein B100 and one molecule of apolipoprotein(a). Lp(a) is synthesized by the liver and its assembly occurs at the hepatocyte cell membrane surface. Lp(a) has been shown to promote thrombosis, by preventing the conversion of plasminogen to plasmin and to participate to wound healing and tissue repair (Riches and Porter, 2012). Lp(a) has also been described as an acute-phase reactant in various disorders. High levels of Lp(a) correlates with an increased risk of cardiovascular diseases and are found in patients with Rheumatoid Arthritis (Govindan et al., 2015; Saeedi and Frohlich, 2016).
Bioclinica Lab employs uses the quantitative immunoturbidimetry method for the measurement of human Lp(a) in serum.
Govindan, K.P.S., Basha, S., Ramesh, V., Kumar, C.N., and Swathi, S. (2015). A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects. J. Pharm. Bioallied Sci. 7, S22–S25.
Riches, K., and Porter, K.E. (2012). Lipoprotein(a): Cellular Effects and Molecular Mechanisms. Cholesterol 2012, e923289.
Saeedi, R., and Frohlich, J. (2016). Lipoprotein (a), an independent cardiovascular risk marker. Clin. Diabetes Endocrinol. 2, 7.